

# Slovenia

Total population as of 31 October 2023, Eurostat<sup>1</sup>: 2 107 180

## Tuberculosis cases, 2022

### Notifications

|                                                            |            |
|------------------------------------------------------------|------------|
| Total number of cases                                      | 74         |
| Notification rate per 100 000                              | 3.5        |
| New <sup>a</sup> and relapse                               | 72         |
| New <sup>a</sup> and relapse notification rate per 100 000 | 3.4        |
| Pulmonary                                                  | 61 (82.4%) |
| of which microscopy-positive                               | 31 (50.8%) |
| of which laboratory-confirmed                              | 58 (95.1%) |
| Laboratory-confirmed TB cases                              | 67 (90.5%) |
| Mean age of new native TB cases                            | 59.2 years |
| Mean age of new foreign TB cases                           | 51.6 years |
| Foreign origin of all TB cases                             | 31 (41.9%) |
| New (not previously treated)                               | 68 (91.9%) |

### Estimate

|                                                     |            |
|-----------------------------------------------------|------------|
| Estimated new and relapse cases, N, best [low-high] | 83 [71-96] |
|-----------------------------------------------------|------------|

<sup>a</sup> Cases with unknown previous TB treatment history included in new cases.

## Drug resistance surveillance and TB/HIV coinfection, 2022

|                                                                                                |             |
|------------------------------------------------------------------------------------------------|-------------|
| Completeness of DRS data <sup>a</sup>                                                          | Yes         |
| Completeness of HIV data <sup>b</sup>                                                          | Yes         |
| Case-linked data-reporting                                                                     | Yes         |
| Cases with DST results                                                                         | 67 (100.0%) |
| Estimated RR-TB among notified bacteriologically confirmed pulmonary cases, N, best [low-high] | 1 [0-1]     |
| Pulmonary RR/MDR-TB cases notified                                                             | 1 (1.7%)    |
| of which pre-XDR-TB cases                                                                      | 1 (100.0%)  |
| Notified RR/MDR-TB                                                                             | 1 (1.5%)    |
| of which pre-XDR-TB cases                                                                      | 1 (100.0%)  |
| TB cases tested for HIV                                                                        | 63 (85.1%)  |
| HIV-positive TB cases                                                                          | 1 (1.6%)    |
| of these on antiretroviral therapy                                                             | -           |

<sup>a</sup> National coverage 100% or culturing ≥ 90%. C+/all TB cases > 50%. DST done for C+ > 75%. EQA ≥ 95%.


<sup>b</sup> More than 50% of TB cases with reported HIV status.

## Treatment outcome monitoring


| Geographical coverage       | National                                                 |                                      |
|-----------------------------|----------------------------------------------------------|--------------------------------------|
| Outcome cohort <sup>a</sup> | New culture positive pulmonary TB cases notified in 2021 | All RR/MDR TB cases notified in 2020 |
| Case-linked data-reporting  | Yes                                                      | -                                    |
| Cases notified              | 58                                                       | 1                                    |
| Success                     | 45 (77.6%)                                               | 1 (100.0%)                           |
| Died                        | 7 (12.1%)                                                | 0 (0.0%)                             |
| Failed                      | 0 (0.0%)                                                 | 0 (0.0%)                             |
| Lost to follow-up           | 0 (0.0%)                                                 | 0 (0.0%)                             |
| Still on treatment          | 5 (8.6%)                                                 | 0 (0.0%)                             |
| Not evaluated               | 1 (1.7%)                                                 | 0 (0.0%)                             |

<sup>a</sup> Treatment outcome after 12 months (or 24 months).


## TB notification rates by previous treatment history, 2013–2022




## New and relapse TB cases – notification rates by age group, 2013–2022




## TB cases by geographical origin, 2013–2022




## TB/HIV coinfection, 2013–2022



## RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous treatment history among all TB cases, 2013–2022



## Treatment outcome, new culture-confirmed pulmonary TB cases, 2012–2021



<sup>1</sup> All EU/EEA country population estimates are from Eurostat [website]. Brussels: Eurostat; 2023 (<https://ec.europa.eu/eurostat/home>, accessed 13 February 2024).